Ilinpru (Linagliptin)

Ilinpru is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, acting on the incretin pathway to improve glycaemic control.

• Type 2 diabetes mellitus (adjunct to diet and exercise): improves overall glycaemic control.
• Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
• Type 2 diabetes mellitus (combination therapy): can be combined with other oral antidiabetics for enhanced glucose‑lowering effect.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in increased circulating levels of the incretin hormones GLP‑1 and GIP. Elevated incretins enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, thereby reducing hepatic glucose production and improving post‑prandial glucose control.

Adverse reactions associated with linagliptin are generally mild to moderate, but clinicians should remain vigilant for less common but serious events.

Common Side Effects

• Nasopharyngitis: mild upper respiratory tract infection symptoms.
• Headache: transient, often resolves without intervention.
• Upper respiratory tract infection: cough, sore throat, or congestion.
• Dizziness: occasional light‑headedness.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring immediate medical attention.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Hepatic injury: elevated liver enzymes or jaundice.
• Bullous pemphigoid: rare skin blistering disorder.
• Severe hypoglycaemia: when combined with insulin or sulfonylureas.

When prescribing linagliptin, several safety considerations should be observed.

• Renal impairment: monitor renal function, although dose adjustment is not typically required.
• Hepatic impairment: use with caution and monitor liver enzymes.
• Heart failure: observe for signs of fluid retention.
• Elderly patients: increased vigilance for adverse events.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store below 25°C: keep in the original pack, protect from moisture and light.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Rifampin: may reduce linagliptin plasma concentrations, decreasing effectiveness.
• Strong P‑glycoprotein inducers (e.g., carbamazepine): can lower drug exposure.

Moderate Interactions (Monitor Closely)

• Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed.
• Diuretics: monitor for dehydration and renal function.
• ACE inhibitors or ARBs: observe renal function and potassium levels.